No Myth: CEO of ADC upstart calls it quits; Bristol Myers vet Jon Wigginton scales new heights at Bright Peak

Alex Nichols

→ When Mythic Therapeutics CEO Alex Nichols spoke to Endpoints News last December about the biotech’s $103 million Series B, he and fellow co-founder Brian Fiske emphasized safety, saying that they’re “really working on trying to overcome what has been one of...

Click to view original post